For instance, SNHG3 is a novel lncRNA that has been identified to have a tumor-suppressor function during papillary thyroid carcinoma (PTC) development, and its silencing can activate tumor progression by modifying the AKT/mTOR/ERK signaling pathway. Here, MAPK1 is linked to neoplasm.